Legend Biotech Corporation (LEGN) ニュース

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

SOMERSET, N.J., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 millionMHRA and Health...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

SOMERSET, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]